Paris-based Servier, a global independent pharmaceutical Group, and Nymirum, a pioneer in RNA-targeted small molecules, have entered into a strategic collaboration to identify and develop RNA-modulatory drugs for the treatment of neurological diseases.

Under the collaboration agreement, Nymirum will leverage its proprietary DART Platform (Dynamic atomic-resolution RNA Targeting Platform) to discover novel small molecule therapeutics for multiple neurological targets. Servier is responsible for joint preclinical development and has the right to pursue further development on the current targets as well as expand the scope of the collaboration. The collaboration provides Nymirum with an initial payment, followed by future success payments.

"We are excited to pair Nymirum's expertise in targeting RNA with Servier's experience in CNS (Central Nervous System) to advance transformative therapies. The ability to resolve and leverage RNA's dynamic structure opens a new chapter for drug discovery, enabling novel programs across all therapeutic areas," said Joshua Fairbank, Chief Executive Officer and Co-Founder of Nymirum.

"This new collaboration is the opportunity to progress innovative RNA-targeted approaches towards clinical assessment in patients with very limited or absent treatment options," stated Ross Jeggo, Global Head of Neuroscience and Immuno-inflammation Therapeutic Area at Servier. 

Multiple drug discovery projects, harnessing the Nymirum platform to deliver RNA-targeting small molecules for neurodegenerative diseases. The therapeutic advantage associated with a small molecule versus other DNA- or RNA-based approaches is innovative and very promising for potential treatments for patients suffering from disorders of the central nervous system.